September 28, 2023 – After greater than a dozen reports of intestinal blockages in people taking the diabetes drug Ozempic, the FDA announced that the doubtless life-threatening condition will probably be listed on the drug's label.
The medical term for intestinal obstruction is “ileus,” and the FDA has received 18 reports of this in people taking Ozempic.
The FDA has greater than 8,500 Reports of gastrointestinal problems in people doping up corresponding to Ozempic and Wegovy, the latter approved for weight reduction. Ileus is mentioned in 33 cases, including two deaths, during which people took medications containing semaglutide, the energetic ingredient in Ozempic, Wegovy and one other widely used weight reduction drug called Mounjaro.
Semaglutide works by mimicking a hormone called glucagon-like peptide-1 (GLP-1), which targets regions of the brain that regulate appetite and food intake. The package inserts for Mounjaro, Ozempic and Wegovy already mention that delayed gastric emptying may occur. Taking semaglutide is related to significant weight reduction, often within the range of 15% of body weight.
The FDA didn't go to date as to say a direct link between Ozempic and intestinal obstruction.
“Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure,” the said the FDA when agreeing to the label update.
The same warning concerning the risk of intestinal obstruction is already on the labels for Mounjaro And ways.
The label change comes after a girl from Louisiana Lawsuit filed It claims she was “seriously injured” after taking Mounjaro and Ozempic, and that the pharmaceutical corporations did not disclose the chance that the drugs could cause vomiting and diarrhea as a result of inflammation of the stomach lining, in addition to the chance of stomach paralysis (often known as gastroparesis).